Essential Pharma acquires European rights to Colobreathe®(colistimethate sodium) from Teva Colobreathe® is an inhaled antibiotic for the management of chronic Pseudomonas aeruginosa infections in cystic fibrosis patients The acquisition will help ensure continued access to an important medicine for this vulnerable patient population First rare disease medicine to be added to the Essential Pharma product portfolio Zug, Switzerland and Egham, UK – 8 January 2024 – Essential Pharma, an international specialty pharma group focused on ensuring that patients have sustainable access to low volume, clinically well-established pharmaceutical products across key therapeutic areas, announces that it has completed the acquisition of European rights to Colobreathe® from Teva Laboratories UK Limited.

Essential Pharma从Teva Colobreathe®获得了Colobreathe®（colistimethate sodium）的欧洲权利。Colobreathe®是一种吸入性抗生素，用于治疗囊性纤维化患者的慢性铜绿假单胞菌感染。此次收购将有助于确保这一弱势患者群体继续获得重要药物，这是第一种添加到Essential中的罕见病药物制药产品组合瑞士祖格和英国埃格姆–2024年1月8日–Essential Pharma，一家国际专业制药集团，专注于确保患者在关键治疗领域可持续获得低容量，临床成熟的制药产品，宣布已完成从Teva Laboratories UK Limited收购Colobreathe®的欧洲权利。

Colobreathe® is indicated for the management of chronic pulmonary infections due to Pseudomonas aeruginosa (PsA) in patients with cystic fibrosis aged 6 years and older. Bacterial lung infection with PsA is frequent in cystic fibrosis patients due to the accumulation of mucus in the lungs which allows bacteria to grow more easily causing infections, lung damage and breathing problems.1 There are two elements to Colobreathe®, a capsule containing the active pharmaceutical ingredient and a Turbospin inhaler to deliver the drug.

Colobreathe®适用于治疗6岁及以上囊性纤维化患者因铜绿假单胞菌（PsA）引起的慢性肺部感染。囊性纤维化患者中PsA的细菌性肺部感染很常见，因为肺部粘液的积累使细菌更容易生长，从而导致感染，肺损伤和呼吸问题。Colobreathe®有两种成分，一种含有活性药物成分的胶囊和一种用于输送药物的Turbospin吸入器。

Under the terms of the acquisition, Essential Pharma has acquired the rights to Colobreathe® across European markets; the product is currently marketed across more than 20 countries in Europe, including the UK. The acquisition represents the first rare disease product acquisition for the group and further establishes Essential Pharma as a leading specialty pharma business ensuring the continual supply of niche medicines of high clinical importance to patients, heal.

根据收购条款，Essential Pharma已在欧洲市场收购Colobreathe®的权利；该产品目前在包括英国在内的20多个欧洲国家销售。此次收购是该集团首次收购罕见病产品，并进一步将Essential Pharma确立为领先的专业制药企业，确保持续为患者提供具有高度临床重要性的利基药物heal。